Skip to main content
    V

    Vir Biotechnology Inc (VIR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.25
    -0.33 (-3.44%)

    Market Cap: $1.64B

    Last updated: Nov 17, 2026 at 4:28 PM ET

    Vir Biotechnology Inc (VIR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Vir Biotechnology (VIR) has a market cap of $1.64B and an enterprise value of $1.42B. Revenue grew 1697.56% over the last 12 months from the 12 months before. Its share count is up 21.84% from a year earlier.

    Total Valuation

    Enterprise value is 13.34% below the market cap, as cash exceeds debt.

    Market Cap$1.64B
    Enterprise Value$1.42B
    Latest price (Nov 17, 2026)$9.25

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.93% in the quarter ended Sep 30, 2026 and grew 11.30% a year over 2 years.

    Shares Outstanding169.28M
    Shares Change (YoY)+21.84%
    Shares Change (QoQ)+0.93%
    Share Count Growth (2Y CAGR)+11.30%

    Valuation Ratios

    Sales and book value multiples are 5.2x and 1.7x. Its year-end P/S ranged from 2.1x to 62.6x from 2019 to 2025.

    P/S Ratio5.2x
    Forward P/S5.0x
    P/B Ratio1.7x
    P/TBV Ratio1.8x

    Valuation history and multiples

    Price Statistics

    The stock is up 64.30% over 52 weeks and trades 16.44% below its 50-day average.

    Beta (1Y)1.81
    52-Week Change+64.30%
    1-Month Change-9.40%
    3-Month Change-5.32%
    6-Month Change+8.44%
    5-Year Change-70.05%
    Total Return (1Y)+64.30%
    Total Return (3Y CAGR)-1.54%
    Total Return (5Y CAGR)-21.84%
    Return vs SPY (1Y)+56.62%
    Max Drawdown (1Y)-32.21%
    Max Drawdown (3Y)-66.19%
    Sharpe Ratio (1Y)0.78
    Correlation with SPY (1Y)0.37
    50-Day Average$11.07
    200-Day Average$9.78
    52-Week Range$5.32 to $14.38
    RSI (14 Days)37.1
    Average Volume (20 Days)3.04M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.30x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.30x
    Quick Ratio6.30x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -20.62% over the last 12 months, against a 5-year average of -15.91%.

    Return on Equity (ROE)-20.62%
    Return on Assets (ROA)-16.62%
    ROE (5Y Average)-15.91%
    ROA (5Y Average)-13.52%
    ROIC (5Y Average)-62.46%
    Asset Turnover0.28x

    Scores

    VIR has an Altman Z-Score of 2.75, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score2.75
    Altman Z ZoneGrey
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $303.07M over the last 12 months.

    Revenue$303.07M
    Revenue Growth (YoY)+1697.56%
    Gross Profit$303.05M
    Operating Income-$211.40M
    Pretax Income-$184.72M
    Net Income-$184.79M
    Reported EPS (TTM)-$1.26

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 80.72% of the $1.11B in total assets.

    Cash and Equivalents$218.87M
    Total Debt$0
    Net Cash$218.87M
    Net Cash Per Share$1.29
    Working Capital$427.61M
    Shareholder Equity$896.04M
    Book Value Per Share$5.29
    Tangible Book Value$871.47M
    Tangible Book Per Share$5.15
    Total Assets$1.11B
    Total Liabilities$215.82M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $804.00K of capital spending, operating cash flow left -$141.82M of free cash flow.

    Operating Cash Flow-$141.02M
    Capital Expenditures$804.00K
    Free Cash Flow-$141.82M
    FCF Per Share-$0.84
    Depreciation and Amortization$14.29M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -69.75%.

    Gross Margin100.00%
    Operating Margin-69.75%
    Pretax Margin-60.95%
    Net Margin-60.97%
    FCF Margin-46.80%
    Gross Margin (5Y Average)96.11%

    Growth

    Revenue fell 65.12% a year over 3 years.

    Revenue Growth (3Y CAGR)-65.12%
    Revenue Growth (5Y CAGR)-2.14%
    Book Value Per Share Growth (2Y CAGR)-31.79%
    Tangible Book Per Share Growth (2Y CAGR)-32.05%

    Revenue and profit by year

    Dividends and Yields

    VIR does not pay a dividend. Its free cash flow yield is -9.06%.

    FCF Yield-9.06%
    Buyback Yield-15.35%
    Shareholder Yield-15.35%

    Peer Position

    Against 10 similar companies, VIR has the 7th highest P/S.

    P/S Ratio5.2x vs 10.8x median
    Revenue Growth (Trailing 4 Quarters, YoY)+1697.56% vs +12.82% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -1.33% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-1.33%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VIR

    What is VIR's market cap?

    Vir Biotechnology has a market cap of $1.64B. Its enterprise value, which adds debt and subtracts cash, is $1.42B.

    How many shares of VIR are outstanding?

    Vir Biotechnology has 169.28M shares outstanding. The count is up 21.84% from a year earlier.

    Does VIR pay a dividend?

    No. Vir Biotechnology does not pay a dividend.

    How much debt does VIR have?

    Vir Biotechnology has $0 of total debt and $218.87M of cash and equivalents, a net cash position of $218.87M.